FDA will hold antimicrobial resistance meeting
Executive Summary
On April 28, FDA will hold a public hearing to discuss strategies to limit the development of antimicrobial resistance and the possible effectiveness of economic incentives in promoting development of new antimicrobial agents. Under FDAAA, FDA is required to hold such a public hearing to discuss which life-threatening infectious diseases potentially qualify for grants and contracts under the Orphan Drug Act. In February, the agency was criticized by industry reps at a CAP workshop for not providing clear guidance on what it is looking for in anti-infective drug development, and not offering enough incentives for sponsors to continue R&D in the area
You may also be interested in...
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.